Mertk targeting in 129P2 ES cells results in a robust anti-tumor response against immune checkpoint inhibitor (ICI)-refractory YUMM1.7 melanoma and GL261 brain tumor, but this effect is not phenocopied in Mertk-/-V2 or Mertk-/-V3 mice. Here, MERTK is linked to neoplasm.